NOVO B Novo Nordisk A/S Class B

Novo Nordisk A/S - Share repurchase programme

Novo Nordisk A/S - Share repurchase programme

Bagsværd, Denmark, 30 March 2020 – On 5 February 2020, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 17 billion to be executed during a 12-month period beginning 5 February 2020.

Under the programme, initiated 5 February 2020, Novo Nordisk will repurchase B shares for an amount up to DKK 2.9 billion in the period from 5 February 2020 to 4 May 2020.

Since the announcement as of 23 March 2020, the following transactions have been made:

 Number of

B shares
Average

purchase price
Transaction

value, DKK
Accumulated, last announcement3,840,000 1,571,827,702
23 March 2020135,000352.7147,615,969
24 March 2020130,000358.2146,567,603
25 March 2020130,000364.5347,388,349
26 March 2020130,000375.0748,759,710
27 March 2020130,000376.5648,952,200
Accumulated under the programme4,495,000 1,811,111,533

The details for each transaction made under the share repurchase programme are published on .

Transactions related to Novo Nordisk’s incentive programmes have resulted in a net transfer from Novo Nordisk of 10,425 B shares in the period from 23 March 2020 to 27 March 2020. The shares in these transactions were not part of the Safe Harbour repurchase programme.

With the transactions stated above, Novo Nordisk owns a total of 54,523,609 B shares of DKK 0.20, corresponding to 2.3% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,400,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 17 billion during a 12-month period beginning 5 February 2020. As of 27 March 2020, Novo Nordisk has since 5 February 2020 repurchased a total of 4,495,000 B shares at an average share price of DKK 402.92 per B share equal to a transaction value of DKK 1,811,111,533.

Further information

Media:  
Anne Margrethe Hauge
Ken Inchausti (US)
   
Investors:  
Daniel Muusmann Bohsen
Valdemar Borum Svarrer
Ann Søndermølle Rendbæk
Mark Joseph Root
Kristoffer Due Berg (US)

Company announcement No 20 / 2020

Attachment

EN
30/03/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Novo Nordisk A/S Class B

Rune Majlund Dahl
  • Rune Majlund Dahl

Novo Nordisk (Buy, TP: DKK900.00) - Subdued prescription growth in Q1

We have updated our model with the latest IQVIA data, and see downside risk to Visible Alpha consensus. We see Q1e global sales for Wegovy of DKK17,898m (c2.2% below consensus) and Ozempic of DKK31,642m (c1.5% below consensus). While a reaffirmation of guidance could offer relief, we have lowered our target price, primarily on lower-than-expected GLP-1 sales. We reiterate our BUY but have cut our target price to DKK900 (1,040).

Rune Majlund Dahl
  • Rune Majlund Dahl

Zealand Pharma (Buy, TP: DKK1150.00) - Deal delivery

We are positive on the partnership with Roche for petrelintide and view the financial terms as favourable for Zealand Pharma. While we had included Roche as the partner for petrelintide in our base case, the deal terms are better than we assumed. Thus, we have updated our valuation for petrelintide to DKK731 NPV/share. We reiterate our BUY and have increased our target price to DKK1,150 (1,010), based on our SOTP NPV.

Rune Majlund Dahl
  • Rune Majlund Dahl

Zealand Pharma (Buy, TP: DKK1010.00) - Poised for big news

Q4 revenue was DKK9.1m, driven by the Zegalogue licence and development agreement with Novo Nordisk, and EBIT was DKK-399.3m (we forecast DKK-370.1m, consensus DKK-367.6m). The 2025 opex guidance was for DKK2,000m–2,500m, reflecting pipeline progression investments. We expect strong pipeline news flow in H1, including dapiglutide headline results and potentially a petrelintide partnership. We reiterate our BUY and DKK1,010 target price.

Rune Majlund Dahl
  • Rune Majlund Dahl

Zealand Pharma (Buy, TP: DKK1010.00) - Focus on partnership discussion...

We expect an uneventful Q4 report, but with investor focus on the ongoing petrelintide partnership discussions. Our base case derives DKK593/share for petrelintide, assuming a profit-sharing agreement in H1. We believe recruitment for the petrelintide phase II trial will be completed in H1 (headline results in Q1 2026e) and look for 2025 opex guidance of DKK1,750m–1,850m. We reiterate our BUY and DKK1,010 target price.

Novo Nordisk AS: 1 director

A director at Novo Nordisk AS sold after exercising options/sold 40,000 shares at 620.260DKK and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch